^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    γ-secretase inhibitor

    Related drugs:
    4d
    Distinct and shared effects of individual γ-secretase inhibitors on human keratinocytes. (PubMed, JID Innov)
    We used pharmacological inhibitors of γ-secretase (SCP0004, nirogacestat, and E2012) that have different mechanisms of action and substrate selectivity (eg, notch processing). Thus, γ-secretase inhibitors can drive keratinocyte functions associated with HS development. Future studies elucidating the contribution of specific substrates may inform the mechanisms of drug-induced HS phenotypes.
    Journal
    |
    CDH1 (Cadherin 1) • APP (Amyloid Beta Precursor Protein)
    |
    Ogsiveo (nirogacestat)
    23d
    A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants (clinicaltrials.gov)
    P1, N=20, Recruiting, Immunome, Inc.
    New P1 trial
    |
    varegacestat (AL102)
    23d
    Novel NOTCH1-unmutated T-ALL Cell Line With Suppressed Growth by Gamma-secretase Inhibitors. (PubMed, Anticancer Res)
    Alternative mechanisms link GSIs to the regulation of HES1 and MYC. TMD11 provides a unique model for probing NOTCH-independent GSI actions and screening novel targeted therapeutics in NOTCH-unmutated T-ALL.
    Preclinical • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NOTCH1 (Notch 1) • HES1 (Hes Family BHLH Transcription Factor 1)
    1m
    Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (clinicaltrials.gov)
    P1, N=73, Completed, Allogene Therapeutics | Active, not recruiting --> Completed | N=132 --> 73
    Trial completion • Enrollment change • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Ogsiveo (nirogacestat) • ALLO-715 • ALLO-647
    2ms
    To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=20, Completed, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Active, not recruiting --> Completed
    Trial completion
    |
    Ogsiveo (nirogacestat) • midazolam hydrochloride • omeprazole
    2ms
    Nirogacestat in Patients With Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, AIDS Malignancy Consortium
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Ogsiveo (nirogacestat)
    2ms
    A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2032 --> Apr 2027
    Trial completion date
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Ogsiveo (nirogacestat)
    2ms
    Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (clinicaltrials.gov)
    P4, N=50, Recruiting, SpringWorks Therapeutics, Inc.
    Trial initiation date
    |
    Ogsiveo (nirogacestat)
    2ms
    A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, SpringWorks Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2030 --> Oct 2029 | Trial primary completion date: May 2028 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Ogsiveo (nirogacestat)
    3ms
    Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat (clinicaltrials.gov)
    P1, N=24, Completed, SpringWorks Therapeutics, Inc. | Recruiting --> Completed
    Trial completion
    |
    Ogsiveo (nirogacestat)
    3ms
    To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, SpringWorks Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026
    Enrollment closed • Trial completion date • Trial initiation date
    |
    Ogsiveo (nirogacestat) • midazolam hydrochloride • omeprazole
    3ms
    A Varegacestat Hepatic Impairment Study (clinicaltrials.gov)
    P1, N=35, Completed, Immunome, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    varegacestat (AL102)